Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation
George N Ioannou, Kristin Berry, Nallakkandi Rajeevan, Yuli Li, Pradeep Mutalik, Lei Yan, David Bui, Francesca Cunningham, Denise M Hynes, Mazhgan Rowneki, Amy Bohnert, Edward J Boyko, Theodore J Iwashyna, Matthew L Maciejewski, Thomas F Osborne, Elizabeth M Viglianti, Mihaela Aslan, Grant D Huang, Kristina L Bajema, George N Ioannou, Kristin Berry, Nallakkandi Rajeevan, Yuli Li, Pradeep Mutalik, Lei Yan, David Bui, Francesca Cunningham, Denise M Hynes, Mazhgan Rowneki, Amy Bohnert, Edward J Boyko, Theodore J Iwashyna, Matthew L Maciejewski, Thomas F Osborne, Elizabeth M Viglianti, Mihaela Aslan, Grant D Huang, Kristina L Bajema
Abstract
Background: COVID-19 has been linked to the development of many post-COVID-19 conditions (PCCs) after acute infection. Limited information is available on the effectiveness of oral antivirals used to treat acute COVID-19 in preventing the development of PCCs.
Objective: To measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing PCCs.
Design: Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment.
Setting: Veterans Health Administration (VHA).
Participants: Nonhospitalized veterans in VHA care who were at risk for severe COVID-19 and tested positive for SARS-CoV-2 during January through July 2022.
Intervention: Nirmatrelvir-ritonavir treatment for acute COVID-19.
Measurements: Cumulative incidence of 31 potential PCCs at 31 to 180 days after treatment or a matched index date, including cardiac, pulmonary, renal, thromboembolic, gastrointestinal, neurologic, mental health, musculoskeletal, endocrine, and general conditions and symptoms.
Results: Eighty-six percent of the participants were male, with a median age of 66 years, and 17.5% were unvaccinated. Baseline characteristics were well balanced between participants treated with nirmatrelvir-ritonavir and matched untreated comparators. No differences were observed between participants treated with nirmatrelvir-ritonavir (n = 9593) and their matched untreated comparators in the incidence of most PCCs examined individually or grouped by organ system, except for lower combined risk for venous thromboembolism and pulmonary embolism (subhazard ratio, 0.65 [95% CI, 0.44 to 0.97]; cumulative incidence difference, -0.29 percentage points [CI, -0.52 to -0.05 percentage points]).
Limitations: Ascertainment of PCCs using International Classification of Diseases, 10th Revision, codes may be inaccurate. Evaluation of many outcomes could have resulted in spurious associations with combined thromboembolic events by chance.
Conclusion: Out of 31 potential PCCs, only combined thromboembolic events seemed to be reduced by nirmatrelvir-ritonavir.
Primary funding source: U.S. Department of Veterans Affairs.
Conflict of interest statement
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-1394.
Figures
References
- Crook H, Raza S, Nowell J, et al. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648. [PMID: ] doi:10.1136/bmj.n1648
- Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12:6571. [PMID: ] doi:10.1038/s41467-021-26513-3
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259-264. [PMID: ] doi:10.1038/s41586-021-03553-9
- Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583-590. [PMID: ] doi:10.1038/s41591-022-01689-3
- Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. [PMID: ] doi:10.1136/bmj.n693
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-232. [PMID: ] doi:10.1016/S0140-6736(20)32656-8
- Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-605. [PMID: ] doi:10.1001/jama.2020.12603
- Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. [PMID: ] doi:10.1136/bmj.n1098
- Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599-607. [PMID: ] doi:10.1016/S0140-6736(21)00896-5
- Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017-1032. [PMID: ] doi:10.1038/s41591-020-0968-3
- Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. [PMID: ] doi:10.1038/s41591-021-01283-z
- Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146. [PMID: ] doi:10.1038/s41579-022-00846-2
- Bull-Otterson L, Baca S, Saydah S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years—United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71:713-717. doi:10.15585/mmwr.mm7121e1
- National Institutes of Health. COVID-19 Treatment Guidelines: Therapeutic Management of Nonhospitalized Adults With COVID-19. Updated 21 July 2023. Accessed at on 19 May 2023.
- Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among U.S. veterans: target trial emulation studies with one-month and six-month outcomes. Ann Intern Med. 2023;176:807-816. [PMID: ] doi:10.7326/M22-3565
- Yan L, Streja E, Li Y, et al. Anti-SARS-CoV-2 pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023. JAMA Netw Open. 2023;6:e2331249. [PMID: ] doi:10.1001/jamanetworkopen.2023.31249
- U.S. Department of Health and Human Services. COVID-19 Therapeutics Thresholds, Orders, and Replenishment. Accessed at on 6 September 2023.
- Hammond J, Leister-Tebbe H, Gardner A, et al.; EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-1408. [PMID: ] doi:10.1056/NEJMoa2118542
- Butler CC, Hobbs FDR, Gbinigie OA, et al.; PANORAMIC Trial Collaborative Group. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281-293. [PMID: ] doi:10.1016/S0140-6736(22)02597-1
- Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183:554-564. [PMID: ] doi:10.1001/jamainternmed.2023.0743
- Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. [PMID: ] doi:10.1136/bmj-2022-074572
- Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758-764. [PMID: ] doi:10.1093/aje/kwv254
- Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N Engl J Med. 2022;386:105-115. [PMID: ] doi:10.1056/NEJMoa2115463
- Ioannou GN, Locke ER, O'Hare AM, et al. COVID-19 vaccination effectiveness against infection or death in a national U.S. health care system: a target trial emulation study. Ann Intern Med. 2022;175:352-361. [PMID: ] doi:10.7326/M21-3256
- Ioannou GN, Locke ER, Green PK, et al. Comparison of Moderna versus Pfizer–BioNTech COVID-19 vaccine outcomes: a target trial emulation study in the U.S. Veterans Affairs healthcare system. EClinicalMedicine. 2022;45:101326. [PMID: ] doi:10.1016/j.eclinm.2022.101326
- Labrecque JA, Swanson SA. Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol. 2017;32:473-475. [PMID: ] doi:10.1007/s10654-017-0293-4
- Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Updated 9 February 2023. Accessed at on 10 May 2022.
- U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. Accessed at on 20 May 2023.
- U.S. Food and Drug Administration. Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers. Accessed at on 21 May 2023.
- National Academies of Sciences, Engineering, and Medicine. Facilities Staffing Requirements for the Veterans Health Administration—Resource Planning and Methodology for the Future: Interim Report. National Academies Pr; 2019. [10.17226/25455]
- National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Board on Human-Systems Integration; Division on Engineering and Physical Sciences; Board on Infrastructure and the Constructed Environment; Committee on Facilities Staffing Requirements for Veterans Health Administration. Facilities Staffing Requirements for the Veterans Health Administration—Resource Planning and Methodology for the Future. National Academies Pr; 2019. [10.17226/25454] [32293829]
- Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524. doi:10.2307/2288398
- Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022;376:e068993. [PMID: ] doi:10.1136/bmj-2021-068993
- Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414. [PMID: ] doi:10.1136/bmj-2021-068414
- Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495. [PMID: ] doi:10.1136/bmj.319.7223.1492
- StataCorp. Stata Manual. Chapter 11: Language syntax. Stata Pr; 2023. Accessed at on 21 May 2023.
- Austin PC, Cafri G. Variance estimation when using propensity-score matching with replacement with survival or time-to-event outcomes. Stat Med. 2020;39:1623-1640. [PMID: ] doi:10.1002/sim.8502
- Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560. [PMID: ] doi:10.1097/00001648-200009000-00011
- Wang L, Porter B, Maynard C, et al. Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration. Med Care. 2013;51:368-373. [PMID: ] doi:10.1097/MLR.0b013e31827da95a
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al.; MOVe-OUT Study Group. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-520. [PMID: ] doi:10.1056/NEJMoa2116044
- Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23:696-705. [PMID: ] doi:10.1016/S1473-3099(23)00011-7
- Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387:790-798. [PMID: ] doi:10.1056/NEJMoa2204919
- Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176:77-84. [PMID: ] doi:10.7326/M22-2141
- Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76:e342-e349. [PMID: ] doi:10.1093/cid/ciac443
- Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong Kong: an observational study. Lancet. 2022;400:1213-1222. [PMID: ] doi:10.1016/S0140-6736(22)01586-0
- Yip TCF, Lui GCY, Lai MSM, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis. 2023;76:e26-e33. [PMID: ] doi:10.1093/cid/ciac687
- Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23:806-815. [PMID: ] doi:10.1016/S1473-3099(23)00118-4
- Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;380:e072705. [PMID: ] doi:10.1136/bmj-2022-072705
Source: PubMed